Cargando…

Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab: A case report

RATIONALE: Pseudoprogression, that is, initial tumor growth followed by subsequent tumor regression, has been well described for immunomodulation therapy in melanoma patients. This phenomenon is not well defined in lung cancer. Nivolumab, an anti-PD-1 monoclonal antibody, was recently approved for n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sarfaty, Michal, Moore, Assaf, Dudnik, Elizabeth, Peled, Nir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2017
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5287964/ https://www.ncbi.nlm.nih.gov/pubmed/28121940 http://dx.doi.org/10.1097/MD.0000000000005951

Ejemplares similares

Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: Case report
por: Chen, Yu-Hsiu, et al.
Publicado: (2017)

Pseudoprogression in the era of immunotherapy-based strategies for recurrent head and neck squamous cell carcinoma achieving complete response: A case report
por: Zhou, Jiawei, et al.
Publicado: (2023)

Apatinib combined with temozolomide treatment for pseudoprogression in glioblastoma: A case report
por: Zhao, Mingming, et al.
Publicado: (2022)

Pathological pseudoprogression to anti-PD-1 inhibitor in metastatic periampullary carcinoma: Case report
por: Wang, Junhui, et al.
Publicado: (2023)

Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report
por: Ozaki, Yukinori, et al.
Publicado: (2017)

Efficacy of short-term nivolumab treatment in a Chinese patient with relapsed advanced-stage lung squamous cell carcinoma: A case report
por: Pi, Guoliang, et al.
Publicado: (2016)

Next-generation sequencing in thyroid cancers: do targetable alterations lead to a therapeutic advantage?: A multicenter experience
por: Moore, Assaf, et al.
Publicado: (2021)

The incidence of pseudoprogressive disease associated with programmed cell death 1/programmed cell death ligand 1 inhibitors: A meta-analysis
por: Zhang, Jingyi, et al.
Publicado: (2021)

A Rare Delayed Atypical Pseudoprogression in Nivolumab-Treated Non-Small-Cell Lung Cancer
por: Suyanto, Suyanto, et al.
Publicado: (2019)

Skeletal muscle mass predicts the outcome of nivolumab treatment for non-small cell lung cancer
por: Tsukagoshi, Mariko, et al.
Publicado: (2020)

Lung brain metastasis pseudoprogression after nivolumab and ipilimumab combination treatment
por: Melian, Marcos, et al.
Publicado: (2018)

Diffuse alveolar hemorrhage with pseudoprogression during nivolumab therapy in a patient with malignant melanoma
por: Ikeda, Takaya, et al.
Publicado: (2018)

A case report of immune checkpoint inhibitor nivolumab combined with anti-angiogenesis agent anlotinib for advanced esophageal squamous cell carcinoma
por: Tang, Yong, et al.
Publicado: (2019)

Intratumoral Heterogeneity of Subcutaneous Nodules in a Never-Smoker Woman of Lung Squamous Cell Carcinoma Detected on (18)F-Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography: A Case Report
por: Zhao, Qian, et al.
Publicado: (2015)

Nivolumab as adjuvant treatment for a spinal melanocytoma: A case report
por: Hean, Virginie, et al.
Publicado: (2021)

Nivolumab plus regorafenib in patients with small bowel adenocarcinoma: A case report
por: Zhang, Gairong, et al.
Publicado: (2021)

Atypical response with bone pseudoprogression in a patient receiving nivolumab for advanced cutaneous squamous cell carcinoma
por: Oliveira, Leandro J. C., et al.
Publicado: (2018)

Case report: pathological complete response in an IIIB non-small cell lung cancer patient after preoperative neoadjuvant nivolumab therapy combined with chemotherapy
por: Li, Luzhen, et al.
Publicado: (2022)

The risks of hematological toxicities of nivolumab in cancer patients: A PRISMA-compliant meta-analysis
por: Shi, Zuolin, et al.
Publicado: (2022)

Dramatic response to osimertinib combined with crizotinib in EGFR T790 M mutation only in blood and Met amplification only in tumor tissue expressive non-small cell lung cancer: A case report
por: Li, Dapeng, et al.
Publicado: (2021)

Network module function enrichment analysis of lung squamous cell carcinoma and lung adenocarcinoma
por: Li, Piaopiao, et al.
Publicado: (2022)

Delayed pseudoprogression of lung adenocarcinoma accompanied with interstitial lung disease during chemotherapy after nivolumab treatment
por: Kumagai, Toru, et al.
Publicado: (2017)

Nivolumab Induced Lethal Aplastic Anemia in a Patient with Metastatic Melanoma
por: Rouvinov, Keren, et al.
Publicado: (2019)

The different benefits and side effects of nivolumab combined with ipilimumab in diverse cancer: A Protocol for Systematic Review
por: Tong, Hongxuan, et al.
Publicado: (2020)

Invasion Types Are Associated With Poor Prognosis in Lung Squamous Carcinoma Patients
por: Zhao, Yang, et al.
Publicado: (2015)

Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab
por: Kato, Ryoji, et al.
Publicado: (2017)

Pseudoprogression with Neoadjuvant Immunotherapy for Cutaneous Melanoma
por: Garcia, Diogo, et al.
Publicado: (2021)

A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy
por: Hirasawa, Yuya, et al.
Publicado: (2021)

Exploration of immune-related cells and ceRNA in squamous cell lung cancer
por: Wang, Lijun, et al.
Publicado: (2021)

Epithelial-mesenchymal transition-related gene signature for prognosis of lung squamous cell carcinoma
por: Yu, Hongmin, et al.
Publicado: (2023)

Bicytopenia in Primary Lung Melanoma Treated with Nivolumab
por: Takahashi, Ayumu, et al.
Publicado: (2018)

Whole exome sequencing of independent lung adenocarcinoma, lung squamous cell carcinoma, and malignant peritoneal mesothelioma: A case report
por: Vanni, Irene, et al.
Publicado: (2016)

A case report of tongue metastasis from lung squamous cell carcinoma and literature review
por: Cheng, Xiaolong, et al.
Publicado: (2017)

Prognostic impact of eosinophils in peripheral blood and tumor site in patients with esophageal squamous cell carcinoma treated with concurrent chemoradiotherapy
por: Yang, Xiyue, et al.
Publicado: (2021)

Risk factors of lymph node metastasis in lung squamous cell carcinoma of 3 cm or less in diameter
por: Huang, Lijian, et al.
Publicado: (2017)

Nivolumab in Non-Small Cell Lung Cancer: Real World Long-Term Survival Results and Blood-Based Efficacy Biomarkers
por: Daher, Sameh, et al.
Publicado: (2021)

Esophago-tracheobronchial fistula following treatment of anlotinib in advanced squamous cell lung cancer: Two case reports
por: Zhang, Pin-Liang, et al.
Publicado: (2019)

Case Report: Pseudoprogression With Nivolumab and Bevacizumab Followed by Recurrent Immune-Related Pneumonitis in Urothelial Carcinoma With Lung Metastasis
por: Yang, Zizhong, et al.
Publicado: (2021)

Unusual jaw metastasis from squamous cell lung cancer in heavy smoker: Two case reports and review of the literature
por: Pezzuto, Aldo, et al.
Publicado: (2017)

Familial aggregation of subcutaneous panniculitis-like T cell lymphoma: A case report of monozygotic twin brothers
por: Shen, Xun-Ze, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_16v38dmfpj33pq84muou8arv9g